Dean Petkanas - 29 Jul 2021 Form 4 Insider Report for NEUROPATHIX, INC.

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Dean Petkanas
Issuer symbol: N/A
Transactions as of: 29 Jul 2021
Net transactions value: +$90,000
Form type: 4
Filing time: 02 Aug 2021, 08:04:09 UTC
Next filing: 02 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NPTX	Common Stock	Award	$90,000	+1,875,000	+8.2%	$0.0480	24,859,029	29 Jul 2021	See Note	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person agreed to accept 1,875,000 restricted shares of the issuers common stock in exchange for the discharge of an aggregate of $90,000 of accrued but unpaid monies payable by the issuer to the reporting person as a portion of his salary. The issuance was completed on July 29, 2021. The price of the shares acquired by the reporting person is equal to the closing price of the Company's common stock on July 28, 2021, which was $0.048 per share.
F2	Aggregate amount of shares beneficially owned by the reporting person includes shares held by him directly as well as indirectly through Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC. The reporting person disclaims beneficial ownership of the securities held by Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC, except to the extent of his pecuniary interest therein.

Content

The reporting person agreed to accept 1,875,000 restricted shares of the issuers common stock in exchange for the discharge of an aggregate of $90,000 of accrued but unpaid monies payable by the issuer to the reporting person as a portion of his salary. The issuance was completed on July 29, 2021. The price of the shares acquired by the reporting person is equal to the closing price of the Company's common stock on July 28, 2021, which was $0.048 per share.

Aggregate amount of shares beneficially owned by the reporting person includes shares held by him directly as well as indirectly through Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC. The reporting person disclaims beneficial ownership of the securities held by Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC, except to the extent of his pecuniary interest therein.